34P - Association of ACRBP gene polymorphism (+26A/G) to liver cancer and diabetes leads to novel biomarker discovery

Background

Several studies have shown statistical evidence of linkage between ACRBP gene and Liver. cancer. It might therefore be considered as a candidate gene for liver cancer research. This study. investigated the relationship between the ACRBP gene and the risk for liver cancer.

Methods

The study was carried out with dry and wet lab approaches to identify the most deleterious SNP (Single nucleotide polymorphism) and their association for the diagnosis of LC as novel biomarker. With an array of available SNP data on dbSNP we sorted out functional SNPs in ACRBP gene by implementing different authentic computational tools for functional and structural assessment, molecular dynamics, and energy minimization studies. Thereafter we have employed 42 samples of LC pateintsin Bangladesh and healthy control to observe the association with our identified nsSNP by experimental validation (extraction, amplification, digestion and sequencing method).

Results

Out of a total 1008 SNPs in ACRBP, we investigated 198 coding nonsynonymous SNPs (nsSNPs) and observed that 8 of them could be expected to alter the protein’s function based on the predictions of both sequence homology–based and structural homology–based algorithms. By analyzing multiple tools having different perspectives an aggregate result were produced where rs11545745 (Q26R) nsSNP was found to be most likely to exert deleterious effect. 3D model of mutated protein was generated to determine the functional and structural effect of the mutations on ACRBP. Further we have verified rs11545745 polymorphism with liver cancer patients using polymerase chain reaction–restriction fragment length polymorphism (PCR- RFLP) method. A total of 28 patients with LC and 14 healthy control individuals were included for experimental validation. The frequency of the allelic distribution (G) (p< 0.0126) and genotype (GG) (p<0.0026) was found significant in LC patient.

Conclusions

Our study suggests that ACRBP functional polymorphisms (+26A/G) might possibly be associated with cancer and play a role in the pathogenesis of LC. Our findings indicate that rs11545745 could be a novel biomarker in LC patients diagnosis though detailed study on more LC patients need to be performed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.